Labcorp (NYSE:LH) Director Sells $954,060.00 in Stock

Key Points

• Labcorp Director Kerrii Anderson sold 3,000 shares for approximately $954,060 under a pre-arranged Rule 10b5-1 plan, reducing her direct holdings by 31.37% to 6,563 shares.
• Labcorp reported quarterly revenue of $3.73 billion and adjusted EPS of $4.99, exceeding analyst expectations, while revenue rose 5.8% year over year. The company issued full-year 2026 EPS guidance of $18.10–$18.55.
• The company declared a quarterly dividend of $0.72 per share, equivalent to a 0.9% yield, and analysts maintain a “Moderate Buy” consensus with an average price target of $330.

Labcorp Holdings Inc. (NYSE:LH - Get Free Report) Director Kerrii Anderson sold 3,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company's stock, valued at $2,087,165.26. The trade was a 31.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Stock Up 1.6%

Shares of NYSE:LH opened at $323.18 on Tuesday. The stock's 50-day moving average price is $287.48 and its two-hundred day moving average price is $275.09. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $326.89. The firm has a market cap of $26.21 billion, a price-to-earnings ratio of 26.73, a PEG ratio of 1.84 and a beta of 0.87.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the business posted $4.35 EPS. The company's quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp's payout ratio is presently 23.82%.

Institutional Investors Weigh In On Labcorp

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company's stock worth $2,471,326,000 after buying an additional 37,197 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company's stock valued at $1,343,922,000 after acquiring an additional 2,719,475 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company's stock valued at $607,241,000 after buying an additional 22,170 shares during the period. Geode Capital Management LLC raised its position in shares of Labcorp by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company's stock valued at $534,023,000 after acquiring an additional 13,775 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company's stock worth $604,488,000 after purchasing an additional 289,029 shares during the period. Institutional investors own 95.94% of the company's stock.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $306.00 target price on shares of Labcorp in a research report on Friday, July 31st. Robert W. Baird set a $352.00 target price on shares of Labcorp in a report on Friday, July 31st. Weiss Ratings raised Labcorp from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Barclays raised their price objective on shares of Labcorp from $290.00 to $320.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. Finally, Mizuho set a $355.00 target price on Labcorp in a research note on Monday, August 10th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $330.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source